To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00702845
First received: June 18, 2008
Last updated: April 10, 2015
Last verified: April 2015
  Purpose

Clinical trial objectives are to investigate the efficacy and safety of a single injection of 100 μg Org 36286 in women weighing 60 kg or less to induce multifollicular development for controlled ovarian stimulation (COS), using daily recFSH as a reference.


Condition Intervention Phase
Infertility
Drug: corifollitropin alfa (Org 36286)
Drug: recFSH (follitropin beta)
Drug: gonadatropin releasing hormone (GnRH) antagonist (ganirelix)
Drug: human chorion gonadatropin (hCG)
Biological: progesterone
Drug: placebo-recFSH (follitropin alfa)
Drug: placebo-corifollitropin alfa
Biological: open-label recFSH
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-blind, Active-controlled, Equivalence Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of 100 µg Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Number of Cumulus-oocyte-complexes Retrieved, Per Attempt [ Time Frame: One COS cycle with cumulus-oocyte-complex retrieval (up to a maximum total duration of 21 days) ] [ Designated as safety issue: No ]
    The primary efficacy parameter was defined as the number of cumulus-oocyte-complexes retrieved from participants in a controlled ovarian stimulation (COS) cycle for in vitro fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI). For participants who did not have cumulus-oocyte-complex retrieval, the number retrieved was set to zero.


Secondary Outcome Measures:
  • Total Dose of recFSH Administered [ Time Frame: One COS cycle (up to a maximum total duration of 19 stimulation days) ] [ Designated as safety issue: No ]
    Total dose of recFSH (IU) administered was defined as the total amount of recFSH needed by participants to reach the criterion for administration of hCG (at least 3 follicles >=17mm).

  • Total Dose of recFSH Administered From Day 8 Onwards [ Time Frame: Stimulation Day 8 of COS cycle up to day of hCG administration (up to a maximum total duration of 19 stimulation days) ] [ Designated as safety issue: No ]
    Total dose of recFSH (IU) needed from Stimulation Day 8 onwards to reach the criterion for administration of hCG (at least 3 follicles >=17mm).

  • Number of Days Treated With recFSH [ Time Frame: One COS cycle (up to a maximum total duration of 19 stimulation days) ] [ Designated as safety issue: No ]
    Numbers of days treated with recFSH was defined as the total number of days participants received recFSH (excluding coasting days) until they reached the criterion for administration of hCG (at least 3 follicles >=17mm).

  • Total Duration of Stimulation (Days) [ Time Frame: One COS cycle (up to a maximum total duration of 19 stimulation days) ] [ Designated as safety issue: No ]
    Total duration of stimulation was defined as the number of days from first drug administration up to and including the Day of hCG administration.

  • Serum Follicle Stimulating Hormone (FSH) Levels (Restricted to Participants With hCG Injection) [ Time Frame: Predose up to 2 weeks after ET (up to maximum of 6 weeks) ] [ Designated as safety issue: No ]
    Blood samples for assessment of serum FSH were taken prior to injection on Stimulation Day 1, Day 3, Day 5, Day 8, Day of hCG, Day of ET, at the visit two weeks after ET.

  • Serum Lutenizing Hormone (LH) Levels (Restricted to Participants With hCG Injection) [ Time Frame: Predose up to 2 weeks after ET (up to maximum of 6 weeks) ] [ Designated as safety issue: No ]
    Blood samples for assessment of serum LH were taken prior to injection on Stimulation Day 1, Day 3, Day 5, Day 8, Day of hCG, Day of ET, at the visit two weeks after ET.

  • Serum Estradiol (E2) Levels (Restricted to Participants With hCG Injection) [ Time Frame: Predose up to 2 weeks after ET (up to maximum of 6 weeks) ] [ Designated as safety issue: No ]
    Blood samples for assessment of serum E2 were taken prior to injection on Stimulation Day 1, Day 3, Day 5, Day 8, Day of hCG, Day of ET, at the visit two weeks after ET.

  • Serum Progesterone (P) Levels (Restricted to Participants With hCG Injection) [ Time Frame: Predose up to 2 weeks after ET (up to maximum of 6 weeks) ] [ Designated as safety issue: No ]
    Blood samples for assessment of serum P were taken prior to injection on Stimulation Day 1, Day 3, Day 5, Day 8, Day of hCG, Day of ET, at the visit two weeks after ET.

  • Serum Inhibin-B Levels (Restricted to Participants With hCG Injection) [ Time Frame: Predose up to 2 weeks after ET (up to maximum of 6 weeks) ] [ Designated as safety issue: No ]
    Blood samples for assessment of serum inhibin-B were taken prior to injection on Stimulation Day 1, Day 3, Day 5, Day 8, Day of hCG, Day of ET, at the visit two weeks after ET.

  • Number and Size Distribution of Follicles During Stimulation and on the Day of hCG Administration [ Time Frame: Predose up to day of hCG administration (up to a maximum total duration of 19 stimulation days, including day of hCG administration) ] [ Designated as safety issue: No ]
    For each participant, the number of follicles ≥11 mm, ≥15 mm, and ≥17 mm, documented by ultrasonography on defined days during the treatment cycle, was calculated.

  • Number and Quality of Oocytes Assessed Prior to ICSI (Restricted to Participants With ICSI Only) [ Time Frame: Up to 36 hours after administration of hCG ] [ Designated as safety issue: No ]
    The number of oocytes used for ICSI was assessed and categorized based on their quality (i.e., metaphase I oocytes, metaphase II oocytes, and germinal vesicles stage oocytes).

  • Fertilization Rate [ Time Frame: Up to 10 weeks after ET ] [ Designated as safety issue: No ]
    Fertilization rate, defined as 100 times the ratio of the number of fertilized 2 pronuclei (PN) oocytes obtained and the number of oocytes incubated, was tabulated for each treatment group.

  • Number and Quality of Embryos Obtained at Day 3 (Restricted to Participants With IVF and/or ICSI) [ Time Frame: Post fertilization Day 3 (up to a maximum of 2 days after hCG administration) ] [ Designated as safety issue: No ]
    Embryo quality was rated Grade 1, 2, 3, or other. Grade 1 represented excellent quality; Grade 2 good quality; Grade 3 fair quality. "Other" grade embryos were those that did not qualify as Grade 1, 2, or 3.

  • Implantation Rate for Participants With ET [ Time Frame: Up to 6 weeks after ET within a treatment cycle (up to a maximum 10 weeks) ] [ Designated as safety issue: No ]
    The implantation rate was defined as 100 times the maximum number of gestational sacs as assessed by any ultrasound scan (USS) after ET divided by the number of embryos transferred (per participant), maximized to 100%.

  • Number of Participants With Miscarriages [ Time Frame: Up to 10 weeks after ET (up to a maximum of 14 weeks) ] [ Designated as safety issue: No ]
    A miscarriage, also known as a "spontaneous abortion," was defined as the loss of a fetus without induction or instrumentation.

  • Number of Participants With Pregnancies [ Time Frame: Up to 10 weeks after ET (up to a maximum of 14 weeks) ] [ Designated as safety issue: No ]
    A Biochemical Pregnancy was defined as a pregnancy proven by a biochemical pregnancy test. (Participants not having a positive biochemical pregnancy test result, but with an ultrasound showing at least one gestational sac were counted as having a biochemical pregnancy.) A Clinical Pregnancy was defined as the presence of at least one gestational sac as assessed by an USS scan. A Vital Pregnancy was considered the presence of at least one fetus with heart activity as assessed by USS. An Ongoing Pregnancy was defined as the presence of at least one fetus with heart activity at least 10 weeks after ET as assessed by USS or Doppler, or confirmed by live birth.


Enrollment: 397
Study Start Date: January 2007
Study Completion Date: December 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: corifollitropin alfa 100 µg
Participants received a single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular [IM] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
Drug: corifollitropin alfa (Org 36286)
100 µg corifollitropin alfa subcutaneous (SC) injection
Other Name: Org 36286
Drug: gonadatropin releasing hormone (GnRH) antagonist (ganirelix)
GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
Drug: human chorion gonadatropin (hCG)
hCG 5,000 IU or 10,000 IU administered SC
Biological: progesterone
Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
Drug: placebo-recFSH (follitropin alfa)
Placebo-recFSH administered at the equivalent volume of 150 IU/day.
Biological: open-label recFSH
Open-label recFSH administered up to a maximum dose of 200 IU/day.
Active Comparator: recFSH 150 IU
Participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
Drug: recFSH (follitropin beta)
150 IU recFSH SC injection
Other Name: recFSH (Puregon/Follistim AQ Cartridge)
Drug: gonadatropin releasing hormone (GnRH) antagonist (ganirelix)
GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
Drug: human chorion gonadatropin (hCG)
hCG 5,000 IU or 10,000 IU administered SC
Biological: progesterone
Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
Drug: placebo-corifollitropin alfa
Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.
Biological: open-label recFSH
Open-label recFSH administered up to a maximum dose of 200 IU/day.

Detailed Description:

This is a randomized, double-blind, active-controlled, equivalence clinical trial investigating the efficacy and safety of a new treatment regimen with Org 36286, a recombinant gonadotropin applied to initiate and sustain follicular stimulation in COS for Assisted Reproductive Technology (ART). For this regimen, patients receive a single injection of Org 36286 and one week later, treatment is continued with daily recFSH up to the day of triggering final oocyte maturation. In the reference group patients receive daily injections of recFSH up to the day of triggering final oocyte maturation. Equivalence between the two treatment groups in the number of oocytes retrieved is the primary objective of this trial.

  Eligibility

Ages Eligible for Study:   18 Years to 36 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Females of couples with an indication for COS and IVF or ICSI;
  • >=18 and <= 36 years of age at the time of signing informed consent;
  • Body weight <= 60 kg and BMI >= 18 and <= 32 kg/m^2;
  • Normal menstrual cycle length: 24-35 days;
  • Availability of ejaculatory sperm (use of donated and/or cryopreserved sperm is allowed);
  • Willing and able to sign informed consent.

Exclusion Criteria:

  • History of/or any current (treated) endocrine abnormality;
  • History of ovarian hyper-response or ovarian hyperstimulation syndrome

(OHSS);

  • History of/or current polycystic ovary syndrome (PCOS);
  • More than 20 basal antral follicles <11 mm (both ovaries combined) as measured on USS in the early follicular phase (menstrual cycle day 2-5);
  • Less than 2 ovaries or any other ovarian abnormality (including endometrioma > 10 mm; visible on USS);
  • Presence of unilateral or bilateral hydrosalphinx (visible on USS);
  • Presence of any clinically relevant pathology affecting the uterine cavity or fibroids >= 5 cm;
  • More than three unsuccessful IVF cycles since the last established ongoing

pregnancy (if applicable);

  • History of non- or low ovarian response to FSH/hMG treatment;
  • History of recurrent miscarriage (3 or more, even when unexplained);
  • FSH > 12 IU/L or LH > 12 IU/L as measured by the local laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5);
  • Any clinically relevant abnormal laboratory value based on a sample taken during the screening phase;
  • Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts);
  • Recent history of/or current epilepsy, HIV infection, diabetes, cardiovascular,

gastro-intestinal, hepatic, renal or pulmonary disease;

  • Abnormal karyotyping of the patient or her partner (if karyotyping is performed);
  • Smoking more than 5 cigarettes per day;
  • History or presence of alcohol or drug abuse within 12 months prior to signing informed consent;
  • Previous use of Org 36286;
  • Use of hormonal preparations within 1 month prior to randomization;
  • Hypersensitivity to any of the concomitant medication prescribed as part of the treatment regimen in this protocol;
  • Administration of investigational drugs within three months prior to signing informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00702845

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Director Merck Sharp & Dohme Corp.
  More Information

Publications:
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00702845     History of Changes
Other Study ID Numbers: P05690, 2006-003811-36, 107012
Study First Received: June 18, 2008
Results First Received: April 10, 2015
Last Updated: April 10, 2015
Health Authority: Austria: Federal Office for Safety in Health Care
Czech Republic: State Institute for Drug Control
Denmark: Danish Medicines Agency
Spain: Ministry of Health and Consumption
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Sweden: Medical Products Agency
South Korea: Korea Food and Drug Administration (KFDA)
Taiwan: Department of Health

Keywords provided by Merck Sharp & Dohme Corp.:
In vitro fertilization
Pharmacological effects of drugs
Hormones
Hormone Substitutes and Hormone Antagonists
Pharmacological Actions
Randomized
Multi-center
Multi-national
Double-blind
Active-controlled
Equivalence

Additional relevant MeSH terms:
Follicle Stimulating Hormone
Ganirelix
Hormones
Progesterone
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Progestins

ClinicalTrials.gov processed this record on June 28, 2015